{"id":436,"date":"2026-04-12T09:05:55","date_gmt":"2026-04-12T09:05:55","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&#038;p=436"},"modified":"2026-08-30T03:53:24","modified_gmt":"2026-08-30T03:53:24","slug":"lucicapiva-capivasertib-200mg-mgx64-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/ar\/product\/lucicapiva-capivasertib-200mg-mgx64-tablets\/","title":{"rendered":"LuciCapiva 200mg"},"content":{"rendered":"<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>HIGHLIGHTS OF PRESCRIBING INFORMATION<\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>These highlights do not include all the information needed to use LuciCapiva safely and effectively. See full prescribing information for LuciCapiva.<\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>&nbsp;<\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>INDICATIONS AND USAGE<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">LuciCapiva is a kinase inhibitor indicated, in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA\/AKT1\/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>DOSAGE AND ADMINISTRATION<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Select patients for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer with LuciCapiva based on the presence of one or more of the following genetic alterations in tumor tissue: PIK3CA\/AKT1\/PTEN.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Recommended Dosage: 400 mg orally twice daily, with or without food,&nbsp;&nbsp;for 4 days followed by 3 days off.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>DOSAGE FORMS AND STRENGTHS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">Tablets: 200 mg\u00d764 tablets<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>CONTRAINDICATIONS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">Severe hypersensitivity to LuciCapiva or any of its components.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>WARNINGS AND PRECAUTIONS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Hyperglycemia: Evaluate blood glucose levels prior to starting and at regular intervals during treatment. Withhold, reduce dose, or permanently discontinue LuciCapiva based on severity.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Diarrhea: LuciCapiva caused diarrhea in most patients. Advise patients to increase oral fluids, start antidiarrheal treatment, and consult with a healthcare provider if diarrhea occurs while taking LuciCapiva. Withhold, reduce dose, or permanently discontinue LuciCapiva based on severity.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Cutaneous Adverse Reactions: Monitor for signs and symptoms of cutaneous adverse reactions. Withhold, reduce dose, or permanently discontinue LuciCapiva based on severity.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Embryo-Fetal Toxicity: LuciCapiva can cause fetal harm. Advise patients of potential risk to a fetus and to use effective contraception.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>ADVERSE REACTIONS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">Most common adverse reactions (incidence \u226520%), including laboratory&nbsp;abnormalities, were diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides, decreased neutrophils, increased creatinine, vomiting and stomatitis.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>DRUG INTERACTIONS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use cannot be avoided, reduce LuciCapiva dose. &nbsp;<\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Moderate CYP3A Inhibitors: Reduce LuciCapiva dose.<\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px;\"><span style=\"font-size:16px;color:#595959\">\u2022&nbsp;Strong and Moderate CYP3A Inducers: Avoid concomitant use.<\/span><\/p>\n<p style=\"margin-top: 2px; margin-right: 27px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>USE IN SPECIFIC POPULATIONS<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">Lactation: Advise not to breastfeed.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\"><strong>Storage<\/strong><strong><\/strong><\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">Store at 20\u2103&nbsp;to 25\u2103&nbsp;(68\u2109&nbsp;to 77\u2109), excursions permitted between 15\u2103&nbsp;and 30\u2103&nbsp;(59\u2109&nbsp;and 86\u2109) [see USP Controlled Room Temperature]. Protect from moisture.<\/span><\/p>\n<p style=\"line-height: 20px;\"><span style=\"font-size:16px;color:#595959\">&nbsp;<\/span><\/p>\n<p><\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LuciCapiva is a kinase inhibitor indicated, in combination with Fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA\/AKT1\/PTEN-alterations as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.<\/p>","protected":false},"featured_media":1949,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[20],"product_tag":[],"class_list":["post-436","product","type-product","status-publish","has-post-thumbnail","product_cat-breast-cancer","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product\/436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/comments?post=436"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/media\/1949"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/media?parent=436"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_brand?post=436"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_cat?post=436"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/ar\/wp-json\/wp\/v2\/product_tag?post=436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}